Disclaimer All products are intended strictly for laboratory research purposes only
Reference: Kaiqiang Sun, Jiuyi Sun, Chen Yan, et
The product appears as a clear, colorless solution with no visible particles
Stay Informed: The Promising Journey of Retatrutide and Whats Next Ongoing Phase III trials aim to confirm retatrutides safety and efficacy in larger populations and diverse indications, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease
The study found that the drug has pharmacological activity on brain structure and function at the 8 mg/day dose as monotherapy or as an add-on to symptomatic treatments
This preparation is designed solely for parenteral use only after addition of solutions that require dilution or must be dissolved in an aqueous vehicle prior